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Background. Although human immunodeﬁciency virus (HIV)-positive persons on antiretroviral therapy (ART) frequently have
chronic liver enzyme elevation (cLEE), the underlying cause is often unclear.
Methods. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study participants without chronic viral hepatitis were
observed to the earliest of cLEE (elevated aminotransferase ≥6 months), death, last follow-up, or January 2, 2014. Antiretroviral
treatment exposure was categorized as follows: no exposure and ongoing short- and long-term exposure (<2 or ≥2 years) after
initiation. Association between development of cLEE and ART exposure was investigated using Poisson regression.
Results. Among 21 485 participants observed for 105 413 person-years (PY), 6368 developed cLEE (incidence 6.04/100 PY; 95%
conﬁdence interval [CI], 5.89–6.19). Chronic liver enzyme elevation was associated with short-and long-term exposure to didano-
sine (<2 years rate ratio [RR] = 1.29, 95% CI, 1.11–1.49; >2 years RR = 1.26, 95% CI, 1.13–1.41); stavudine (<2 years RR = 1.51, 95%
CI, 1.26–1.81; >2 years RR = 1.17, 95% CI, 1.03–1.32), and tenofovir disoproxil fumarate (<2 years RR = 1.55, 95% CI, 1.40–1.72; >2
years RR = 1.18, 95% CI, 1.05–1.32), but only short-term exposure to nevirapine (<2 years RR = 1.44, 95% CI, 1.29–1.61), efavirenz
(<2 years RR = 1.14, 95% CI, 1.03–1.26), emtricitabine (<2 years RR = 1.18, 95% CI, 1.04–1.33), and atazanavir (<2 years RR = 1.20,
95% CI, 1.04–1.38). Chronic liver enzyme elevation was not associated with use of lamivudine, abacavir, and other protease inhib-
itors. Mortality did not differ between participants with and without cLEE.
Conclusions. Although didanosine, stavudine, nevirapine, and efavirenz have been described to be hepatotoxic, we additionally
observed a consistent association between tenofovir and cLEE emerging within the ﬁrst 2 years after drug initiation. This novel
tenofovir-cLEE signal should be further investigated.
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Human immunodeﬁciency virus (HIV)-infection has evolved
into a chronic disease that requires lifelong antiretroviral ther-
apy (ART). Therefore, drug-related toxicities have emerged as a
key issue, including long-term ART-related liver injury [1].
Chronic liver enzyme (alanine aminotransferase [ALT]) eleva-
tion, a marker of persistent hepatocyte injury, is frequent among
HIV-positive persons, even in the absence of hepatitis C (HCV)
and hepatitis B (HBV) coinfection [2–4]. The cause of these ele-
vations, its clinical signiﬁcance, the need for evaluation, a reason-
able diagnostic approach, and its management are often unclear,
particularly when the elevation is modest. Most studies on liver
disease focused on HCV- or HBV-coinfected persons or on the
incidence and prevalence of severely elevated liver enzymes, de-
ﬁned as 3–5 times the upper limit of normal (ULN) or more [5].
Only limited data are available on HIV-monoinfected individuals
with ALT values just above normal limits.
In previous studies, metabolic factors, including obesity, dys-
lipidemia and diabetes mellitus, severe alcohol use, high HIV
viral load, and ART were predictive of persistently elevated
ALT levels [2–4, 6]. Some antiretrovirals, such as the older sta-
vudine (d4T) and didanosine (ddI), have been linked to liver in-
jury [3, 6–11]. Data on the association of newer antiretrovirals
and chronic liver disease are limited.
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Study results on the outcome of liver enzyme elevations are
controversial. A previous analysis of the Data Collection on Ad-
verse Events of Anti-HIV Drugs (D:A:D) Study suggested that
in HIV/HCV-coinfected persons, ALT levels above the normal
limit are associated with a higher mortality [12], whereas in an-
other investigation of HIV-monoinfected persons ALT eleva-
tion was not predictive of an increased death rate, although
the observation period in this study was relatively short [11].
Two liver biopsy series demonstrated a high prevalence of
liver ﬁbrosis (FIB) and steatosis among HIV-monoinfected
adults with chronic elevated liver enzymes [13, 14]. Such results
emphasize that ALT is an important surrogate marker for rele-
vant liver pathology.
Our study aims were (1) to identify risk factors associated
with chronic ALT elevation (cLEE), focusing on the individual
antiretroviral drugs and (2) to evaluate the outcome of liver en-
zyme elevation with regard to liver-related and all-cause mortal-
ity, within the frame of the D:A:D Study with its large size and
long-term prospective observation.
METHODS
Study Design
The D:A:D Study, founded in 1999, is a prospective observa-
tional study of 11 previously established cohorts as described
in detail [15]. Currently, more than 49 000 HIV-positive partic-
ipants are followed in Europe, the United States, and Australia.
The primary study aim was to investigate the associations be-
tween exposure to antiretroviral drugs and risk of myocardial
infarction, and, subsequently, other major clinical events. Data,
including sociodemographic characteristics, acquired immune
deﬁciency syndrome (AIDS), viral hepatitis, deaths, known
risk factors for cardiovascular disease, laboratory markers, and
ART, are collected prospectively during routine clinical care. In-
formation on causes of death is captured using the Coding of
Causes of Death in HIV (CoDe) form [16]. Clinical events are
regularly monitored and centrally adjudicated. The present
analyses were limited to the participating cohorts that provided
data on ALT levels.
Deﬁnitions
Chronic ALT elevation was deﬁned as ALT levels greater than
the ULN (males/females >50/>35 U/L) at ≥2 visits spanning
at least 6 months within 2 years. We used the date of the ﬁrst
elevated ALT as the event date. A single normal ALT measure-
ment between 2 elevated values was permitted and therefore did
not signal the end of a period of cLEE. Hepatitis C virus infec-
tion was deﬁned by HCV seropositivity or detectable HCV
RNA. Hepatitis B virus infection was deﬁned by a positive
HBV surface antigen, HBV e antigen, HBV core antibodies,
or detectable HBV DNA. Participants with unknown HBV or
HCV status were excluded. Fibrosis-4 and aspartate amino-
transferase (AST)-to-platelet index (APRI), 2 noninvasive
biomarkers of liver FIB, were calculated as follows: FIB-4:
(age × AST)/[platelet count (109 cells/L) × sqrt(ALT)], and
APRI: [(AST/ULN)/platelet count] × 100. A FIB-4 value >3.25
or an APRI score >1.5 is considered indicative of cirrhosis,
whereas with a FIB-4 ≤ 1.45 and an APRI score ≤0.5, respec-
tively, signiﬁcant FIB is unlikely [17, 18].
Statistical Analyses
Cohort-speciﬁc baseline dates were chosen according to the in-
troduction of routine ALTmonitoring in the individual cohorts.
All D:A:D participants without HBV and HCV infection, with
≥3 ALT measurements, ≥6 months of follow-up, and normal
ALT at baseline, were followed from baseline to the earliest of
cLEE, death, 6 months prior to a date of a ﬁrst positive HCV/
HBV test, 6 months after last visit, or February 1, 2014. The in-
cidence of cLEE was deﬁned as the number of ﬁrst events divid-
ed by the total person years of follow-up (PYFU).
We used Poisson regression models to assess the incidence of
cLEE and its association with ART and other risk factors. Mod-
els were manually built using a standard structured approach
including variables into a multivariable model in groups. At
each stage, factors that were not signiﬁcantly associated with
cLEE were removed before moving to the next set of variables.
Fixed covariables were sex, ethnicity, and participating cohort.
Time-updated covariables were age, calendar year, hypercholes-
terolemia, hypertriglyceridemia, use of lipid-lowering drugs,
lipodystrophy, body mass index (BMI), arterial hypertension,
smoking status, and exposure to the individual antiretrovirals.
Antiretroviral therapy exposure was categorized as follows for
each individual drug: no exposure, ongoing short- and long-
term exposure (<2 or ≥2 years) after initiation; and discon-
tinuation for <2 or ≥2 years. We do not present risk estimates
for drugs after discontinuation because interpretation is difﬁ-
cult without considering the subsequent drugs persons were
switched to. Use of ritonavir (RTV) includes both full and
boosting doses.
We also investigated the association between the total num-
ber and duration of cLEE episodes with all-cause mortality
using Poisson regression models. For these analyses, individuals
were followed to the earliest of death, 6 months prior to a date of
a ﬁrst positive HCV/HBV test, 6 months after last visit, or Feb-
ruary 1, 2014, and all periods of cLEE, including any subsequent
episodes, were included. Analyses were adjusted for age, sex,
ethnicity, mode of HIV acquisition, calendar year, cohort,
smoking status, BMI, and in a subsequent model additionally
for time-updated CD4 cell counts and HIV viral loads. Note
that these models did not include adjustment for the ART
drugs received, because it was anticipated that any impact of
ART on mortality would be largely driven by changes in CD4
counts and HIV viral loads. Multivariable analyses were not fea-
sible for liver-related deaths because of small numbers. All anal-
yses were performed using SAS version 9.3.
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RESULTS
Patient Characteristics
Of 49 711 participants included in D:A:D until the cutoff date
for the study of February 1, 2014, 29 291 (58.9%) were HCV and
HBV negative and had available ALT results. We further ex-
cluded 3986 (8%) with <3 visits with ALT determinations or
<6 months of follow-up and 3820 participants (7.7%) because
of preexisting elevated ALT levels at time of baseline visit. Ex-
cluded participants were similarly compared with those who
were included in terms of sex, age, ethnicity, mode of HIV ac-
quisition, previous AIDS, and date of D:A:D enrollment, except
that the group with incomplete follow-up contained more
intravenous drug users (IDU) and persons of unknown ethnic-
ity, and the group with increased ALT levels at baseline were
more often IDUs and participants with previous AIDS. The pre-
sent study is thus based on 21 485 HIV-positive individuals
with normal ALT values at baseline (Figure 1).
The study population consisted of 72.9% men with a median
age of 40 years. Of the participants, 51.9% were white, and
51.2% had acquired HIV through sex between men. At study
entry, the median CD4 lymphocyte count was 470 cells/µL
and 72.1% of participants were on ART. In total, 77.2% had
ever been exposed to ART for a median duration of 3.9 years.
Aspartate aminotransferase-to-platelet score was >1.5 in 523
Figure 1. Patient flowchart. ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus.
ART and Risk of Chronic ALT Elevation • OFID • 3
(2.4%) and FIB-4 score was >3.25 in 647 (3.0%) of 12 857 (60%)
persons with available scores (Table 1). Participants contributed
a median of 13 (interquartile range [IQR], 6–23) ALT measure-
ments to the analyses. Overall, the median baseline ALT level
was 22 (IQR, 16–30) U/L.
Predictors for Chronic Alanine Aminotransferase Elevation
During a median follow-up of 6.6 years (IQR, 2.1–10.8) and
105 413 PYFU, 6368 (29.6%) participants experienced episodes
of cLEE, resulting in an incidence of 6.04 per 100 PYFU (95%
CI, 5.89–6.19). Increased BMI (>26 kg/m2), dyslipidemia, use of
lipid-lowering drugs, arterial hypertension, high HIV levels
(≥5 log10 copies/mL), and earlier calendar years were associated
with cLEE. Older age (≥50 years), black ethnicity, male gender,
and current smoking were inversely correlated (Supplementary
Figure 1).
Among the nucleoside reverse-transcriptase inhibitors, cLEE
was associated with ongoing exposure to regimens containing
ddI, d4T, tenofovir disoproxil fumarate (TDF), and with expo-
sure to emtricitabine (FTC) during the ﬁrst 2 years. Exposure to
lamivudine (3TC) was inversely correlated with cLEE. Among
the nonnucleoside reverse-transcriptase inhibitors, the ﬁrst 2
years of exposure to nevirapine (NVP) and efavirenz (EFV)
were only associated with cLEE. The only protease inhibitor
(PI) to demonstrate an association with cLEE was atazanavir
(ATV) during the ﬁrst 2 years of exposure. There was no evi-
dence for an association with increased risk for the other PIs.
Exposure to darunavir, RTV, and ATV for periods in excess
of ≥2 years appeared to be protective for cLEE (Figure 2, Sup-
plementary Table 1).
Because the association of TDF with cLEE was unexpected,
we further analyzed commonly used TDF-containing regimens.
The association was found to be more pronounced when TDF
was used in combination with FTC and/or EFV (Figure 3).
Sensitivity Analyses
To substantiate the positive association between TDF and cLEE, we
performed several sensitivity analyses. First, we excluded all partic-
ipants who acquired HBV/HCV during follow-up, or who ulti-
mately developed end-stage liver disease (ESLD), who might
have received TDF for an unreported HBV infection or because
of its perceived good liver safety proﬁle. Second, we limited the
analyses to ART-naive persons initiating TDF to rule out hepato-
toxicity caused by a previous drug exposure. Third, we used amod-
iﬁed LEE deﬁnition of a single ALT value of ≥100 U/L. Results of
all sensitivity analyses were consistent with our main analyses.
Clinical Outcome
Of the 6368 participants with ≥1 episode of cLEE, 1758 (27.6%)
had at least 1 subsequent additional episode of cLEE. In total, the
participants experienced a median of 1 (IQR, 1–6) episodes of
cLEE with a median total duration of 1.5 (IQR, 0.5–13.7) years.
Overall, 924 persons died over a total of 151 191 PYFU (rate
0.61/100 PYFU; IQR, 0.57–0.65). All-cause mortality was
slightly higher in those who ever had an episode of cLEE com-
pared with participants without cLEE (0.66/100 PYFU versus
0.60/100 PYFU), but this was not signiﬁcant, either when unad-
justed (rate ratio [RR] = 1.10; IQR, 0.95–1.28; P = .19), adjusted
for basic demographic variables (RR = 1.13; IQR, 0.97–1.32;
P = .11), or adjusted additionally for the latest CD4 cell count
Table 1. Baseline Characteristics of 21 485 D:A:D Study Participants
Without HCV or HBV Coinfection
Total of participants, no. (%) 21 485 (100)
Sex, no (%) Male 15 661 (72.9)
Age, years Median (IQR) 40 (33, 49)
Ethnicity, no. (%) White 11 159 (51.9)
Black 2110 (9.8)
Other 580 (2.7)
Unknown 7636 (35.5)
Mode of HIV acquisition, no. (%) Heterosexual 8916 (41.5)
Homosexual 10 990 (51.2)
Injection drug use 243 (1.1)
Other/unknown 1336 (6.2)
Duration of D:A:D cohort follow-up Median (IQR) 6.6 (2.1, 10.8)
Previous clinical AIDS No. (%) 5090 (23.7)
CD4 cells/µL Median (IQR) 470 (318, 656)
Ever received antiretroviral therapy No. (%) 16 578 (77.2)
Cumulative ART exposure (years) Median (IQR) 3.9 (1.8, 7.0)
Ever received NRTIs No. (%) 16 360 (76.2)
Cumulative ART exposure (years) Median (IQR) 3.7 (1.7, 6.7)
Ever received PIs No. (%) 11 922 (55.9)
Cumulative ART exposure (years) Median (IQR) 2.5 (1.1, 4.2)
Ever received NNRTIs No. (%) 10 094 (47.0)
Cumulative ART exposure (years) Median (IQR) 1.9 (0.7, 4.4)
Body mass index, kg/m2, no. (%) <18 545 (2.5)
≥18, ≤26 14 232 (66.2)
>26, ≤30 3129 (14.6)
>30 1154 (5.4)
Unknown 2425 (11.3)
Diabetes mellitus No. (%) 704 (3.3)
Total cholesterol, mmol/L Median (IQR) 5.0 (4.2–5.8)
HDL cholesterol, mmol/L Median (IQR) 1.2 (1.0–1.5)
Triglycerides, mmol/L Median (IQR) 1.5 (1.0–2.4)
Use of lipid-lowering drugs No. (%) 1855 (8.6)
Lipodystrophy No. (%) 4260 (19.8)
Smoking status, n (%) Current 7144 (33.3)
Former 4735 (22.0)
Never 7459 (34.7)
Unknown 2147 (10.0)
FIB-4 score ≤1.45 10 352 (48.2)
>1.45, ≤3.25 1858 (8.7)
>3.25 647 (3.0)
Unknown 8628 (40.2)
APRI score ≤0.5 11 385 (53.0)
>0.5, ≤1.5 949 (4.4)
>1.5 523 (2.4)
Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase;
APRI, aspartate aminotransferase-to-platelet ratio; ART, antiretroviral therapy; D:A:D, Data
Collection on Adverse Events of Anti-HIV Drugs; FIB, fibrosis; HBV, hepatitis B virus; HCV,
hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; IQR,
interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor.
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and HIV viral load (RR = 1.15; IQR, 0.99–1.34; P = .08). Neither
number of episodes of cLEE nor total duration of cLEE was as-
sociated with an increased risk of mortality in unadjusted or ad-
justed analyses (Table 2). The total number of liver-related
deaths was 15 with 5 events among persons with cLEE and 10
events among those without any cLEE.
DISCUSSION
In this large longitudinal cohort analysis, the incidence of cLEE
among HIV-positive individuals without viral hepatitis was
high. In adjusted analyses, cLEE was associated with ongoing
exposure to regimens containing ddI, d4T, and TDF and
short-term exposure to NVP, EFV, FTC, and ATV. However,
mortality did not appear to be increased in HIV-monoinfected
participants with cLEE.
The potential for drug-induced liver toxicity of d4T, ddI,
NVP, and EFV has previously been described [19]. In HIV-
monoinfected and HCV-coinfected individuals, d4T and ddI
have been associated with transaminase elevation, FIB, steatosis,
and ESLD, most likely related to mitochondrial toxicity [3, 6–
10]. In our study, NVP and EFV, known to cause early acute
hepatitis driven by an immune-mediated hypersensitivity reac-
tion, were associated with elevated ALT in the ﬁrst 2 years of
exposure [19, 20].
We were surprised to ﬁnd a strong relationship between TDF
and the development of cLEE emerging within the ﬁrst 2 years
after drug initiation. We conﬁrmed this association using differ-
ent sensitivity analyses. In another recent D:A:D Study of HIV-
monoinfected and HCV/HBV-coinfected participants, TDF
was also found to be associated with ESLD/hepatocellular car-
cinoma, supporting our observation [10]. In addition, our re-
sults are consistent with small case studies [21–24]. There are
a few reports of liver injury and hepatic failure, including 1 per-
son requiring liver transplantation, developing a few months
after starting treatment with TDF/FTC/EFV in persons without
preexisting liver disease [22–24]. Lattuada et al [21] reported on
3 individuals with liver enzyme elevation after the addition of
TDF to an EFV-containing regimen. The drug registration trials
did not identify a link between TDF and hepatotoxicity [25, 26].
The STEAL study, a randomized trial comparing abacavir/3TC
Figure 2. Incidence rate ratios and 95% confidence intervals (CIs) for the devel-
opment of chronic liver enzyme elevation as a function of duration of antiretroviral
drug exposure. Results are from Poisson regression based on 6368 events among
21 485 participants with 105 413 person years of follow-up. Models were adjusted
for exposure to the other antiretrovirals, sex, age, ethnicity, body mass index, lipids,
use of lipid-lowering drugs, lipodystrophy, arterial hypertension, smoking status, cal-
endar year, and participating cohort, and for each drug discontinued for <2 years and
≥2 years. Abbreviations: ABC, abacavir; APV, amprenavir; AZT, zidovudine; AZV, ata-
zanavir; D4T, stavudine; DDI, didanosine; DRV, darunavir; EFV, efavirenz; FTC, emtri-
citabine; LPV, lopinavir; NVP, nevirapine; RTV, ritonavir; TDF, tenofovir disoproxil
fumarate; 3TC, lamivudine.
Figure 3. Incidence rate ratios and 95% confidence intervals (CIs) for the devel-
opment of chronic liver enzyme elevation as a function of duration of antiretroviral
drug exposure. Analyses are based on 6368 events among 21 485 participants with
105 413 person years of follow-up. Poisson regression models were adjusted for ex-
posure to all other antiretrovirals (excluding lamivudine [3TC], emtricitabine [FTC],
efavirenz [EFV], and tenofovir disoproxil fumarate [TDF]), sex, age, ethnicity, body
mass index, lipids, use of lipid lowering drugs, lipodystrophy, arterial hypertension,
smoking status, calendar year, and participating cohort.
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versus TDF/FTC, showed a small but statistically signiﬁcant in-
crease in mean ALT levels on TDF/FTC [27], whereas the AIDS
Clinical Trials Group A5202, a similar study, showed inconsis-
tent results regarding elevated ALT values [28]. Randomized
trials usually enroll participants who are healthier and younger
and may therefore not be representative of the general popula-
tion. Moreover, these trials with viral primary outcomes often
lack statistical power to detect rare adverse drug effects due to
their limited sample size.
The mechanisms of a possible TDF-related liver injury are un-
clear. In vitro data showed that TDF is not associated with mito-
chondrial toxicity [29]. In an animal study, it was found that TDF
induced marked oxidative stress in renal and hepatic tissues of
Wistar rats [30]. Our ﬁnding of the enhanced TDF signal when
used in combination with EFV could reﬂect drug-drug interac-
tions of TDF, which have been described with other antiretrovi-
rals including ddI and ATV [31, 32]. It is interesting to note that
in slow EFV metabolizers, such as those with CYP2B6 loss/
diminished-function alleles, EFV plasma area-under-the-curve
values were highest among patients receiving TDF [33].
In line with other recent reports, most PIs were not associated
with liver toxicity [34]. We found that ATV during the ﬁrst 2
years of exposure was predictive, but with ≥2 years of exposure
ATV was protective for cLEE. In a previous study, ATV was asso-
ciated with grade 3 LEE in HIV/HCV-seropositive individuals
[34], whereas other investigations suggested that liver tolerability
of ATV was good [35, 36]. Continuing surveillance for possible
ATV-related hepatotoxicity is warranted.
Our data conﬁrm that metabolic features, including dyslipi-
demia and a high BMI, are one of the main causes of liver dis-
ease in HIV-positive persons without chronic hepatitis B and
C coinfection, similar to the general population. Our ﬁnding
of black ethnicity as a negative predictor for ALT elevation is
in agreement with other investigations, which found an inverse
association of black ethnicity and hepatic steatosis in the general
population and among HIV-infected patients [37, 38]. A high
HIV viral load was associated with an increased risk of hepat-
opathy compared with individuals on ART with suppressed
viral load, supporting the evidence that HIV itself is contribut-
ing to liver injury [39].
We found a low number of liver-related deaths among HIV-
monoinfected individuals, in accordance with a previous D:A:D
Study [40]. All-cause mortality was not signiﬁcantly increased
among persons with cLEE. Because patients are regularly mon-
itored for their ALT levels, this allows the clinician an early
warning and the possibility to switch drugs or introduce risk
modiﬁcation (eg, alcohol reduction, diet), reducing the poten-
tial impact from ART-related cLEE on mortality. Another pos-
sibility for why we did not see a link between cLEE and
mortality may be a relatively short follow-up period. In the
Table 2. Associations between cLEE, number of Episodes of cLEE, Total Duration of cLEE, and All-Cause Mortalitya
Events
All-Cause Mortality Unadjusted Adjusted (1) Adjusted (2)
Deaths/PY Rate (95% CI)/100 PY RR (95% CI) P Value RR (95% CI) P Value RR (95% CI) P Value
Overall 924/151191 0.61 (.57, .65)
Any cLEE
No 682/114389 0.60 (.55, .64) Ref. Ref. Ref.
Yes 242/36802 0.66 (.57, .74) 1.10 (.95, 1.28) .19 1.13 (.97, 1.32) .11 1.15 (.99, 1.34) .08
No. of episodes of cLEE
None 682/114389 0.60 (.55, .64)
1 192/28835 0.67 (.57, .76)
2 41/6539 0.62 (.43, .82)
3 9/1168 0.77 (.35, 1.46)
≥4 0/230 0 (, 1.60)
Per cLEE 1.05 (.95, 1.17) .35 1.06 (.96, 1.18) .25 1.07 (.96, 1.19) .20
Total duration of cLEE, years
≤0.5 685/117583 0.58 (.54, .63)
>0.5–1 90/13227 0.68 (.54, .82)
>1–1.5 40/5745 0.70 (.48, .91)
>1.5–2 30/3935 0.76 (.49, 1.04)
>2–3 51/4566 1.12 (.81, 1.42)
>3–4 18/2527 0.71 (.42, 1.13)
>4 10/3609 0.28 (.13, .51)
Per year 1.02 (.96, 1.07) .61 1.01 (.95, 1.07) .76 1.01 (.96, 1.07) .67
Abbreviations: CI, confidence interval; cLEE, chronic liver enzyme elevation; HIV, human immunodeficiency virus; PY, patient years; Ref., reference; RR, rate ratio.
a Adjusted for (1) sex, age, ethnicity, mode of HIV acquisition, body mass index, smoking status, calendar year, and participating cohort, and (2) additionally for the latest CD4 cell count and HIV
RNA value.
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large population-based US National Health and Nutrition Ex-
amination Survey III study, elevated ALT levels in HCV/
HBV-negative persons were associated with a higher risk of
liver-related death but not with all-cause death [41]. In contrast,
studies including HCV/HBV-positive persons suggested both
increased liver-related and all-cause mortality among persons
with liver enzyme elevation in the general and HIV-positive
population [12, 42]. Recent data indicate that cLEE is a marker
of serious liver diseases. A large liver biopsy series of HIV-
monoinfected individuals with cLEE revealed in two thirds of
patients signiﬁcant histological abnormalities with nonalcoholic
steatohepatitis (NASH) in 55% and bridging FIB in 17% [14].
Given the long lag time between asymptomatic liver enzyme el-
evation and liver-related death, a study with a longer observa-
tion period may ﬁnd an association between the two.
The strength of this study is its large size and the long-term
prospective observation of a multinational population-based
cohort collaboration. Such large observational studies are crucial
to detect infrequent drug-related toxicities on the population
level. To assess an individual drug effect might be challenging
because antiretrovirals are always used in combination regi-
mens. The large D:A:D Study, however, with extensive follow-
up of patients drawn from heterogeneous settings should allow
to disentangle individual drug effects because there is generally
enough variability in the way an individual drug is used in com-
bination with other drugs. Our study has several limitations. In-
formation on alcohol use was not collected systematically.
However, it is unlikely that the observed associations between
antiretrovirals and cLEE are confounded by alcohol because al-
cohol consumption does not modify a physician’s choice of
ART. Moreover, by excluding HCV/HBV-coinfected persons
and therefore most injection drug users with risk for multiple
substance-dependence syndromes, including alcohol, many
at-risk individuals were excluded. Furthermore, we did not
have information on potentially hepatotoxic non-antiretroviral
drugs. Finally, as a signiﬁcant number of antiretrovirals were in-
cluded in the analysis, we cannot rule out that ﬁndings may be a
result of multiple testing.
CONCLUSIONS
In summary, the long-term observation of HIV-monoin-
fected individuals in this large cohort revealed a high inci-
dence of cLEE. Besides the antiretrovirals ddI, d4T, NVP,
and EFV, previously described to be hepatotoxic, FTC, and
ATV restricted to the ﬁrst 2 years of treatment, we observed
an additional strong association between TDF exposure and
cLEE emerging within the ﬁrst 2 years after drug initiation.
Although mortality was not increased in our study, other
studies found relevant histological abnormalities in HIV-
monoinfected persons, with elevated ALT underscoring its
link to signiﬁcant liver morbidity [13, 14]. In this context, our
results emphasize (1) that ddI and d4T should be avoided if
alternative treatment is available and (2) that close monitoring
of liver enzymes in persons on NVP and EFV is essential. Final-
ly, the observed novel association between TDF and cLEE calls
for further investigations to understand the pathophysiological
mechanisms and its clinical implications. Ongoing surveillance
of drug-related liver injury in large cohort collaborations is of
paramount importance.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Dis-
eases online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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